Press release
Top Players and Competitive Dynamics in the Renin-Angiotensin-System (RAS)-Acting Agents Market
Renin-Angiotensin-System (RAS)-Acting Agents Market
Market Size and Growth Outlook for the Renin-Angiotensin-System (RAS)-Acting Agents Market
The renin-angiotensin-system (RAS)-acting agents market is projected to reach a value of $7.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4%. This steady increase is fueled by several factors including the rising prevalence of chronic kidney disease, growing demand for cardiometabolic medications, better adherence to treatment protocols, and expansion in emerging economies. Additionally, the approval of combination therapies contributes to the forecasted market growth. Key trends shaping this market include increased use of combination antihypertensive treatments, a rise in long-acting cardiovascular drugs, greater emphasis on renal protection therapies, growth in generic RAS drug manufacturing, and a general shift toward fixed-dose combination medications.
Download a free sample of the renin-angiotensin-system (ras)-acting agents market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Factors Supporting the Expansion of the RAS-Acting Agents Market
One major driver of market growth is the increasing burden of chronic kidney disease worldwide, which elevates the need for effective renin-angiotensin system inhibitors. As more patients require management for conditions like hypertension and heart failure, the demand for targeted therapies rises correspondingly. Furthermore, improved patient compliance due to easier dosing regimens, particularly with fixed-dose combinations, is encouraging broader adoption of these medications.
Another important influence is the expansion of healthcare access in emerging markets, where growing awareness and availability of cardiometabolic treatments are fueling demand. Regulatory approvals of combination therapies also play a crucial role in enhancing treatment options for patients, facilitating better clinical outcomes and supporting market progress.
View the full renin-angiotensin-system (ras)-acting agents market report:
https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Major Industry Players in the Renin-Angiotensin-System (RAS)-Acting Agents Sector
Several well-established pharmaceutical companies dominate the RAS-acting agents market, including Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH. Other significant contributors include Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., and Zydus Lifesciences Limited.
A notable development occurred in February 2023, when AstraZeneca, a UK-based pharmaceutical giant, acquired US-based biopharmaceutical company CinCor Pharma for $1.3 billion. This acquisition aims to bolster AstraZeneca's cardiorenal pipeline by adding CinCor's lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor designed to reduce blood pressure in patients with treatment-resistant hypertension.
Emerging Trends Highlighting Innovation in the RAS-Acting Agents Market
Pharmaceutical companies in this market are increasingly focused on developing new renin-angiotensin system inhibitors such as angiotensin-converting enzyme (ACE) inhibitors to improve treatment effectiveness while reducing side effects. These advancements seek to enhance patient compliance and offer better management for hypertension, heart failure, and kidney diseases.
For example, in November 2023, Proveca Ltd., a UK-based drug developer, secured a European Commission grant for pediatric use marketing authorization (PUMA) of Aqumeldi (enalapril maleate) orodispersible tablets. This ACE inhibitor is specifically indicated for treating heart failure in children from birth up to 18 years. By blocking the enzyme that converts angiotensin I to angiotensin II, Aqumeldi helps relax blood vessels, improve blood flow, and reduce cardiac workload in pediatric patients.
Core Segments Defining the Renin-Angiotensin-System (RAS)-Acting Agents Market
The global renin-angiotensin-system (RAS)-acting agents market is categorized into several major segments:
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, and Other Drug Classes.
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, and Coronary Artery Disease.
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Clinics.
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, and Other End-Users.
Further subsegments under drug classes include specific ACE inhibitors such as Captopril, Enalapril, Lisinopril, Ramipril, and Perindopril; ARBs including Losartan, Valsartan, Irbesartan, Olmesartan, and Telmisartan; Renin Inhibitor Aliskiren; Aldosterone Antagonists Spironolactone and Eplerenone; and other drug types like Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), and Angiotensin Receptor Blockers with Neprilysin Inhibitors (ARNBIs).
This comprehensive segmentation provides a detailed framework to understand the market's structure and the various treatment options involved in managing cardiovascular and renal disorders.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Players and Competitive Dynamics in the Renin-Angiotensin-System (RAS)-Acting Agents Market here
News-ID: 4501292 • Views: …
More Releases from The Business Research Company
Key Players and Competitive Dynamics in the Short-Acting Insulin Market
The short-acting insulin market is on track for notable expansion as demand for effective diabetes management solutions continues to rise. Driven by increasing prevalence of type 2 diabetes and advancements in insulin delivery, this market is set to experience steady growth through the end of the decade. Let's explore the market's growth projections, key players, emerging trends, and the breakdown of its segments.
Projected Market Growth and Size of the Short-Acting…
Emerging Sub-Segments Transforming the Small Molecule CMO/CDMO Market Landscape
The small molecule CMO/CDMO sector is poised for significant expansion as the pharmaceutical industry continues to evolve. With growing demands for innovative therapies and streamlined production, this market is set to experience sustained growth through the coming decade. Let's explore the market's size projections, key players, and emerging trends shaping its future trajectory.
Growth Outlook and Market Size for the Small Molecule CMO/CDMO Sector by 2030
The small molecule CMO/CDMO…
Segment Overview, Market Trends, and Competitive Landscape in the Sexually Trans …
The sexually transmitted disease (STD) self-testing market is poised for significant expansion as awareness and technology continue to advance. With growing interest in convenient and private health solutions, this sector is set to experience notable developments driven by innovation and increasing consumer demand. Below is an overview of the market's expected growth, major players, current trends, and key segments shaping the future of at-home STD testing.
Forecasted Growth and Market Size…
Competitive Landscape: Key Market Leaders and Emerging Competitors in the Sleepi …
The sleeping pills market is poised for substantial growth over the coming years, driven by advancements in medication and shifting consumer preferences. As more people seek effective solutions for sleep disorders, innovations and expanding distribution channels are set to play a crucial role in shaping this industry's future. Let's explore the market's expected size, key players, influential trends, and segmentation details to understand its trajectory better.
Projected Market Size of the…
More Releases for RAS
Ras Al Khaimah's Trusted Physiotherapy Service
Unlock Your Body's Potential with Physio Home Professional Physiotherapy Services
At Physio Home in Ras Al Khaimah, we understand the pivotal role that physiotherapy plays in enhancing one's quality of life. Our dedicated team of experts is committed to providing personalized care and effective solutions tailored to your unique needs. With a focus on empowering mobility and promoting holistic well-being, we bring top-tier physiotherapy services directly to your doorstep. Whether you're…
Ras Aquaculture Market Leading Players, Competitive Landscape, Strategy, Forecas …
Ras Aquaculture Market Overview:
Recirculating Aquaculture Systems (RAS) represent an innovative and sustainable approach to aquaculture, focusing on the intensive farming of aquatic organisms in a controlled environment. Unlike traditional aquaculture methods that rely heavily on large water bodies, RAS involves the continuous recirculation and treatment of water within a closed-loop system. This method significantly reduces water usage, minimizes environmental impact, and allows for year-round production regardless of external weather conditions.…
RAS Inhibitors Market Size, Share, Growth Analysis 2023
The global ras inhibitors market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of x% during the forecast period 2023-29. Ongoing research and development efforts in the RAS-inhibitors agents market are expanding its scope. New drugs targeting various renin-angiotensin system components, such as renin, ACE, and angiotensin II receptors, are being explored. The market is also witnessing increased interest…
RAS Targeting Therapies Market, 2021-2031 by Roots
Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings.
To order this 140+ page report, which features 95+ figures, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html
Key Inclusions
A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I /…
RAS Luxury Oils Launches Eco drive Campaign
Luxury Natural Skincare and wellness brand promotes Sustainability for the Environment
One Bottle at a Time #RecyclewithRAS
New Delhi, 26th November 2018: “Farm to bottle’ luxury natural skincare and wellness brand RAS Luxury Oils has launched its eco drive campaign, #RecyclewithRAS to encourage customers, to promote the concept of three R’s -“Reduce, Reuse and Recycle”, and to regain the sustainability of the packaging among customers.
On returning 1 empty primary bottle…
The Kurchatov Institute Has Chosen 2X RAS
Kurchatov Institute - supported by Aflex Distribution - Has Chosen 2X Remote Application Server
"We are very positive about the adoption of a 2X solution. At the moment we are using 2X RAS for its main features: application delivery and load balancing. We are very satisfied with the seamless end-user experience and the high availability gained with the workload-based server load balancing. In future, we plan to use 2X RAS…
